Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, perioperative
- Who it enrolls
- age 60 Years to no upper limit; no BMI minimum stated; conditions: Delirium, Postoperative
- Interventions
- Liraglutide injection; Placebo injection
- Conditions
- Delirium, Postoperative
- Phase and size
- Phase 3 · 260 participants
- Dates
- Start 2024-11-19
Primary completion 2027-03-31 - Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- The incidence of deliriumOne day before surgery and within the first seven days after surgery.
02Eligibility
Who can take part
Inclusion Criteria: 1. Age ≥ 60 years 2. Type 2 diabetes 3. Patients undergoing elective cardiac surgery Exclusion Criteria: 1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc 2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments 3. History of central nervous system damage or surgery 4. Cardiac function NYHA Class IV 5. Severe liver dysfunction (Child-Pugh Class C) 6. Severe renal failure requiring renal replacement therapy 7. History of pancreatitis 8. Type 1 diabetes 9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period 10. Patients with medullary thyroid carcinoma or a family history of it 11. Pregnant or breastfeeding women 12. Intolerance or allergy to liraglutide 13. Previous use of GLP-1A and SGLT2i 14. Patients who refuse to sign the informed consent
03Change log
Registry changes
No changes recorded since the trial was added.